GlassScriptPhysician profile
Rajanish Setty
NPI 1285824219
$4,646.50
in general payments reported to CMS, 2019-2025
15 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,064 · 2020: $425 · 2021: $587 · 2022: $341 · 2023: $39.45 · 2024: $37.13 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,454.65 | 2019-2021 | |
| Coopervision INC. | $1,308.68 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $213.86 | 2022-2025 | Infuse, Biotrue One Day |
| Johnson & Johnson Vision Care, INC. | $167.10 | 2020-2022 | |
| Allergan, INC. | $113.28 | 2020-2022 | |
| Carl Zeiss Meditec USA, INC. | $105.54 | 2021 | |
| Sun Pharmaceutical Industries INC. | $75.79 | 2019-2022 | |
| Alcon Vision LLC | $66.76 | 2019-2022 | |
| Oculus Surgical INC. | $37.13 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $35.24 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $25.86 | 2022 | |
| Optos, INC. | $18.14 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $12.88 | 2019 | |
| Oasis Medical, INC. | $11.59 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$249,998.97 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajanish Setty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.